Top

Rapid Gene Synthesis for Candidate Vaccine Viruses (CVV) Development

Active

2023-73419Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

AI Contract Overview

The contract involves the CDC Influenza Division's requirement for the rapid production of custom genetic materials, specifically plasmids and linear DNA, to support the development of Candidate Vaccine Viruses (CVVs). These CVVs are essential reassortant viruses used as starting materials for both seasonal and pandemic influenza vaccines. Since the genetic makeup of circulating and novel influenza strains is unpredictable and only identified after virus isolation, the contractor will provide flexible, rapid gene synthesis services to meet these evolving needs. The contract will be a Firm Fixed Price agreement awarded through solicitation 75D301-23-R-72646, with a base period of 12 months and four option periods, totaling up to 60 months. The solicitation, under NAICS code 541380 (Testing Laboratories and Services), was expected to be posted on SAM.gov around May 15, 2023, with proposals due by May 29, 2023. The contract will be administered by the CDC Office of Acquisition Services in Atlanta, Georgia, and contact points have been provided for inquiries, though no phone calls will be accepted or returned. This procurement is not a request for capability statements, and all solicitation amendments will be available on the SAM.gov website.

General Info

Firm Fixed Price contract for rapid gene synthesis supporting CDC influenza vaccine development, 60 months.

Agency

Department Of Health And Human Services → CDC Office Of Acquisition Services

NAICS

541380 - Testing Laboratories and Services

Place of Performance

Set-Aside

NONE

Documents

No documents available

Documents will appear here when they are available.

AI Contract Breakdown

Uniform Contract Format

No documents to break down

The breakdown needs solicitation documents. None were found from this contract's source.

Timeline

PhasePresolicitation

PostedMay 8

Presolicitation

Ready to pursue this opportunity?

Start your free trial to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

AgencyDepartment Of Health And Human Services → CDC Office Of Acquisition Services

Contacts2 people available

OfficeATLANTA, GA, 30333, USA

Organization / AgencyDepartment Of Health And Human Services → CDC Office Of Acquisition Services

Office AddressATLANTA, GA, 30333, USA

Contacts

Castrinos Nicholas

contact@example.gov

Timothy Barnes

contact@example.gov

Full Description

CDC Influenza's Division is responsible for the development of Candidate Vaccine Viruses based on circulating and novel influenza strains. Candidate Vaccine Viruses (CVVs) are reassortant viruses which are used as the starting materials for seasonal and pandemic vaccines. To facilitate the development of the CVVs, CDC uses oligonucleotides and synthetic genes to transcribe the influenza genes to produce the CVVs. The Influenza Division requires plasmids and linear DNA to be developed routinely based on the constant changes in the genetic make-up of the circulating and novel viruses. These changes are unpredictable and cannot be identified until the viruses are isolated from patients or infected animals. Overall objective is to provide the Influenza Division with custom rapid genetic products for the development of CVVs. CDC intends to issue a single contract award as a result of solicitation 75D301-23-R-72646. It is anticipated that the resulting contract will be a Firm Fixed Price, Contract. The period of performance will include one 12-month base year and four 12-month option periods, for a total period of performance of 60 months. The Request for Proposal (RFP) will be posted on SAM.gov on or about May 15, 2023. Any amendments issued to the solicitation will also be made at the same website. No response to the notice is required. The NAICS Codes for this proposed procurement is NAICS 541380 Testing Laboratories and Services. The anticipated scheduled solicitation due date will be on or about May 29, 2023. No telephone calls will be accepted or returned. This is not a request for Capability Statements.